-
公开(公告)号:US20200024319A1
公开(公告)日:2020-01-23
申请号:US15565376
申请日:2016-05-04
Applicant: AMGEN INC. , Amgen Inc.
Inventor: Eric Alan BUTZ , Christy Ann THOMSON , Marc Alain GAVIN , Ian Nevin FOLTZ , Dong XIA , Dina N. ALCORN , Ai Ching LIM , Randal Robert KETCHUM , Kathy MANCHULENKO , Laura SEKIROV , Kelly Ann BERRY , Cyr Clovis Chua DE IMUS , Neeraj Jagdish AGRAWAL , Gunasekaran KANNAN , Li LI
Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
-
公开(公告)号:US20210139554A1
公开(公告)日:2021-05-13
申请号:US17065395
申请日:2020-10-07
Applicant: Amgen Inc.
Inventor: Eric Alan BUTZ , Christy Ann THOMSON , Marc Alain GAVIN , Ian Nevin FOLTZ , Dong XIA , Dina N. ALCORN , Randal Robert KETCHEM , Ai Ching LIM , Kathy MANCHULENKO , Laura SEKIROV , Kelly Ann BERRY , Cyr Clovis Chua DE IMUS , Neeraj Jagdish AGRAWAL , Gunasekaran KANNAN , Li LI
Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
-
公开(公告)号:US20240327486A1
公开(公告)日:2024-10-03
申请号:US18627761
申请日:2024-04-05
Applicant: Amgen Inc.
Inventor: Eric Alan BUTZ , Christy Ann THOMSON , Marc Alain GAVIN , Ian Nevin FOLTZ , Dong XIA , Dina N. ALCORN , Randal Robert KETCHEM , Ai Ching LIM , Kathy MANCHULENKO , Laura SEKIROV , Kelly Ann BERRY , Cyr Clovis Chua DE IMUS , Neeraj Jagdish AGRAWAL , Gunasekaran KANNAN , Li LI
CPC classification number: C07K14/55 , A61K38/2013 , A61P37/00 , C07K16/246 , C07K2317/21 , C07K2317/41 , C07K2317/524 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/30
Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
-
公开(公告)号:US20210301020A1
公开(公告)日:2021-09-30
申请号:US17262339
申请日:2019-07-17
Applicant: AMGEN INC.
Inventor: Xin YU , Wenjun OUYANG , Chi-Ming Kevin LI , Jackson Graeme EGEN , Oh Kyu YOON , Ian Halsey DRIVER , Shunsuke TAKENAKA , Christy Ann THOMSON , Hongyu WANG
Abstract: This invention relates to combination therapies comprising a Programmed Death 1 receptor (PD-1) pathway inhibitor, and a Leukocyte Immunoglobulin Like Receptor B (LILRB) signaling inhibitor, and the use of the combination therapies for the treatment of cancer. The invention also relates to the treatment of cancer patients who are refractory to monotherapy with a PD-1 pathway inhibitor.
-
-
-